Principal Investigator - Prof Dame Lesley Fallowfield
Co-Investigator - Prof Val Jenkins
Funder: Boehringer Ingelheim GmBH
AVALPROFS
To determine the 'value' of PFS to patients with metastatic cancer:
- 1 . Patient understanding of therapeutic intent
- 2. Their goals and priorities
- 3.Trade-offs between burdens/toxicities/QoL and Survival (PFS and OS)
- 4. Patient characteristics that under-pin decusuons about treamtment options
- 5. Association of PFS improvement and/or deterioration with QoL and underlying mechanism
- 6. Association of PFS improvement and or deterioration of psychological well-being.
Progression Free Survival (PFS) is commonly used as an endpoint in clinical trials of novel cancer therapies. This study aims to find out what this means for patients. hat they understand about and expect from these treatments and if the benefits from the treatment controlling the cancer make it worth any side effects they could or do experience.
Current Stage:
Archived
Publication
Do drugs offering only PFS maintain quality of life sufficiently from a patient's perspective? Results from AVALPROFS (Assessing the 'VALue' to patients of PROgression Free Survival) study https://doi.org/10.1007/s00520-018-4273-3Publication
Therapeutic aims of drugs offering only Progression Free Survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits https://doi.org/10.1007/s00520-016-3408-7Poster
Hoping against hope: Are patients' expectations and understanding about therapeutic aims of novel drugs similar to their oncologists? posters/Eposter AVALPROFS NCRI 2018.pdfPoster
Assessing the VALue of PROgression Free Survival (AVALPROFS) posters/AVALPROFS at ASCO Palliative Care Conf 23-25 Oct 14.pdfPoster
Assessing the VALue to patients of PROgression Free Survival (AVALPROFS) Quality of Life Results posters/FinalQoLAVALSanDiego11.1.17.pdf
EMAIL: adminshore-c@sussex.ac.uk
PHONE: 01273 873019
TWITTER: https://twitter.com/SussexSHORE_C
LOCATION: MAP